Articles

Find an Article

Filter articles

Applied Filters

Showing 21 to 30 of 122 results

LSIPR 50 2018: Raymond Chen and Kathleen O’Malley

US20-07-2018

Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Scott Gottlieb

US19-07-2018

Scott Gottlieb was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Levelling the medicines playing field

India02-07-2018

Speaking to LSIPR Leena Menghaney, regional head of Médecins Sans Frontières’ Access Campaign in South Asia, explains the importance of a balanced IP policy in fostering healthy generic competition.

Protecting patients, and patents

Canada, Indonesia, Singapore04-06-2018

Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.

Getting into the biosimilars action

US06-03-2018Henk Heus and Ellen Sherin

The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.

From London to Amsterdam: what the EMA’s move means for medicines regulation

EU15-12-2017Rachel Bradley

While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.

LSIPR 50 2017: Jane Philpott

Canada10-11-2017

Jane Philpott was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the government and policy​ ​section, as LSIPR reports.

LSIPR 50 2017: Galit Gonen

UK10-11-2017

Galit Gonen was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.

Data analysis: the highs and lows of generic-filed IPRs

US30-08-2017Wenhua Yu, Stephen Maebius and Tianran Yan

Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner.

New framework for Spanish patentees

Spain28-06-2017

Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.

Showing 21 to 30 of 122 results

LSIPR